Aspirin Social Innovation Award for entrepreneurial social pioneers
Innovative concepts for improving health care provision and nutrition / Bayer Board of Management member Malik:“In the future, we’ll be stepping up our support for social innovations that benefit society” (Source: Bayer Company News)
Source: Bayer Company News - December 16, 2016 Category: Pharmaceuticals Source Type: news
Monsanto Shareowners Approve Merger with Bayer
Key Milestone in Merger to Create a Global Leader in Agriculture / Close of Transaction Expected by the End of 2017 (Source: Bayer Company News)
Source: Bayer Company News - December 13, 2016 Category: Pharmaceuticals Source Type: news
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols / BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions (Source: Bayer Company News)
Source: Bayer Company News - December 12, 2016 Category: Pharmaceuticals Source Type: news
Big Data meets Life Sciences
Key topics in medical and plant research: disease genomics, herbicide resistance, big data analysis for new therapies / Experiencing and understanding the fascination of science: all topics also available in the online edition of research with animated graphics, videos and photo galleries (Source: Bayer Company News)
Source: Bayer Company News - December 12, 2016 Category: Pharmaceuticals Source Type: news
Boehringer Ingelheim Vetmedica, Inc. and Bayer Enter Into Agreement for Purchase of U.S. Cydectin ® Product Portfolio
(Source: Bayer Company News)
Source: Bayer Company News - December 7, 2016 Category: Pharmaceuticals Source Type: news
Bayer successfully places EUR 4 billion of mandatory convertible notes
(Source: Bayer Company News)
Source: Bayer Company News - November 16, 2016 Category: Pharmaceuticals Source Type: news
Bayer to issue mandatory convertible notes
(Source: Bayer Company News)
Source: Bayer Company News - November 15, 2016 Category: Pharmaceuticals Source Type: news
Bayer ’s Xarelto® Significantly Reduced Bleeding Compared to VKA in AF-Patients also Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention (for specialized target groups only)
PIONEER AF-PCI is the first randomised study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Data were presented in a late-breaking clinical trial session at AHA and published simultaneously in The New England Journal of Medicine (Source: Bayer Company News)
Source: Bayer Company News - November 14, 2016 Category: Pharmaceuticals Source Type: news
Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer (for specialized target groups only)
Regulatory submissions in the U.S., Japan and Europe were completed based on data from the Phase III RESORCE study, in which regorafenib demonstrated statistically significant improvement in overall survival / Currently there are no approved therapies for the treatment of unresectable hepatocellular carcinoma (HCC) in the second-line setting (Source: Bayer Company News)
Source: Bayer Company News - November 7, 2016 Category: Pharmaceuticals Source Type: news
Bayer shows strong performance – Acquisition of Monsanto agreed
Group sales increase by 2.3 percent (Fx& portfolio adj. 3.5 percent) to EUR 11,262 million / Pharmaceuticals sustains very good business development / Moderate increase in sales at Consumer Health / Crop Science successful in a persistently difficult market environment / EBITDA before special items up by 6.0 percent to EUR 2,682 million / Net income improves by 18.8 percent to EUR 1,187 million / Core earnings per share increase by 2.4 percent to EUR 1.73 / Forecast for core earnings per share raised / Agreed acquisition of Monsanto creates a global leader in agriculture (Source: Bayer Company News)
Source: Bayer Company News - October 26, 2016 Category: Pharmaceuticals Source Type: news
Bayer an international leader in its sector in climate protection
Board of Management member Dr. Klusik:“Climate protection remains a permanent challenge for society as a whole, and we will continue to make positive contributions” / Institutional investors rely on CDP rating (Source: Bayer Company News)
Source: Bayer Company News - October 25, 2016 Category: Pharmaceuticals Source Type: news
Bayer completes sale of Bayer Garden and Bayer Advanced businesses to SBM
(Source: Bayer Company News)
Source: Bayer Company News - October 5, 2016 Category: Pharmaceuticals Source Type: news
Bayer receives green light for new five-year contraceptive in the EU (for specialized target groups only)
New low dose levonorgestrel-releasing intrauterine system will be named“Kyleena™” / Introduction in Europe is scheduled to start in January 2017 (Source: Bayer Company News)
Source: Bayer Company News - October 4, 2016 Category: Pharmaceuticals Source Type: news
Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - September 28, 2016 Category: Pharmaceuticals Source Type: news
New scholarships worth EUR 345,000 awarded by Bayer Foundation to promote international talents
Support for study projects in the fields of science, agriculture, medicine and teacher training in scientific subjects / Sponsorship for projects abroad in vocational careers as well as a special budget for projects with a focus on Africa / Since 2007, scholarships worth more than EUR 2 million have been awarded to 442 young people (Source: Bayer Company News)
Source: Bayer Company News - September 23, 2016 Category: Pharmaceuticals Source Type: news
